Ocugen Execs Hit With Derivative Suit Over Shoddy Controls

By Sydney Price · July 18, 2024, 6:46 PM EDT

The top brass at biopharmaceutical company Ocugen Inc. were hit with a derivative suit alleging the company's lack of effective internal financial controls caused it to be misvalued and allowed shareholders...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Garg v. MUSUNURI et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

July 17, 2024

Recent Articles By Sydney

November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud